Grifols (GIKLY) Interest & Investment Income (2010 - 2020)
Grifols (GIKLY) posted Interest & Investment Income of $4.9 million for Q2 2018, down 94.57% quarter-over-quarter from $90.3 million in Q1 2018, and up 107.14% year-on-year from $2.4 million in Q2 2017.
Grifols (GIKLY) Interest & Investment Income (2010 - 2020) Analysis & Trends
Grifols (GIKLY) has reported Interest & Investment Income for 8 consecutive years, with $4.9 million the latest figure, recorded in Q2 2018.
- Interest & Investment Income for Q2 2018 came in at $4.9 million, up 107.14% year-over-year; the trailing twelve-month figure through Jun 2018 was $164.3 million (down 12.01% YoY), and the FY2025 annual result was $39.6 million, down 15.83% from the prior year.
- Interest & Investment Income was $4.9 million for Q2 2018 at Grifols, down from $90.3 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $114.5 million in Q4 2016 and troughed at $1.3 million in Q3 2015.
- Average Interest & Investment Income over 4 years is $28.9 million, with a median of $2.8 million recorded in 2016.
- Year-over-year, Interest & Investment Income soared 6525.3% in 2016 and gained 4.19% in 2017.
- Over 4 years, Interest & Investment Income stood at $1.7 million in 2015, then jumped by 6525.3% to $114.5 million in 2016, then slumped by 97.93% to $2.4 million in 2017, then soared by 107.14% to $4.9 million in 2018.
- Per Business Quant data, the three most recent Interest & Investment Income figures were $4.9 million in Q2 2018, $90.3 million in Q1 2018, and $2.4 million in Q2 2017.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 229.00 Mn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -645.00 Mn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 73.00 Mn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2020 | 91.96 Mn |
| Dec 31, 2019 | 270.74 Mn |
| Mar 31, 2019 | 101.50 Mn |
| Dec 31, 2018 | 239.58 Mn |
| Sep 30, 2018 | 235.94 Mn |
| Jun 30, 2018 | 4.90 Mn |
| Mar 31, 2018 | 90.30 Mn |
| Dec 31, 2017 | 237.37 Mn |
| Jun 30, 2017 | 2.37 Mn |
| Mar 31, 2017 | 66.69 Mn |
| Dec 31, 2016 | 114.45 Mn |
| Sep 30, 2016 | 3.17 Mn |
| Jun 30, 2016 | 2.27 Mn |
| Mar 31, 2016 | 56.25 Mn |
| Dec 31, 2015 | 1.73 Mn |
| Sep 30, 2015 | 1.34 Mn |
| Jun 30, 2015 | 1.84 Mn |
| Mar 31, 2015 | 1.58 Mn |
| Dec 31, 2014 | 1.08 Mn |
| Sep 30, 2014 | 1.22 Mn |